“Works on skin” isn’t the same as “works on this skin”
A brand launches a brightening serum with a claim like “clinically proven to reduce dark spots.” The clinical study behind it is real. It’s also, more often than the industry likes to admit, a study run predominantly on lighter skin tones, tested against a form of hyperpigmentation that behaves differently to post-inflammatory hyperpigmentation in melanin-rich skin.
That’s not a marketing problem, it’s an evidence problem, and it’s an increasingly commercial one. Consumers with melanin-rich skin are one of the fastest-growing, most vocal segments calling out exactly this gap, and scrutiny of “clinically proven” claims that don’t specify the skin type they were proven on is only increasing. A claim that isn’t validated on the skin it’s being sold to isn’t a strong claim, it’s a liability with good branding.
Discovery Sprint: finding actives that are right for the skin, not just the category
Most active ingredient screening starts from a general question: what reduces pigmentation, or inflammation, or barrier disruption, across skin broadly. That’s a reasonable starting point, but it’s not the same question as: what reduces post-inflammatory hyperpigmentation specifically in skin where the melanocyte response to inflammation is stronger and longer-lasting.
A Discovery Sprint scoped for melanin-rich skin screens and ranks candidate actives against that second, more specific question. That means weighting for ingredients with tolerability data in darker skin tones, mechanisms that address melanocyte overactivity rather than only surface pigment, and a lower irritation profile, since irritation is what re-triggers the exact response the product is meant to treat.
What a brand gets out of it: a candidate shortlist, the scientific rationale for each one specific to melanin-rich skin biology, screening results, and a recommended lead candidate with a clear next-stage development plan, rather than a generic “top ingredients for hyperpigmentation” list repackaged from existing literature.
Validation Programme: proving it on the skin you’re selling to
This is the step most brands skip, or outsource to a generic lab that runs the same standard efficacy panel regardless of the population the product is aimed at. A Validation Programme scoped for melanin-rich skin runs efficacy testing on and against melanin-rich skin tones specifically, not as a subgroup analysis bolted onto a broader study, but as the actual evidence base for the claim.
That matters most for claims tied directly to the underlying biology, covered in our companion piece, “Why Melanin-Rich Skin Scars Differently“: pigmentation, tone evenness, scarring and mark-fading timelines, and barrier recovery after inflammation. A claim like “reduces the appearance of dark marks” means something different, and needs different evidence, when the population in question has a stronger and longer melanocyte response to begin with.
What a brand gets out of it: mechanism-specific efficacy data, benchmarking against comparable products where relevant, and a technical report written to support the actual wording of a claim, not just a general “tested” stamp.
What Claims-Ready evidence actually looks like
In practice, a Claims-Ready Validation for a melanin-rich skin claim typically covers three layers, not one: a core efficacy assay showing the active does what it’s meant to do, a mechanism investigation showing why it works on melanocyte-driven pigmentation specifically rather than pigmentation generally, and benchmarking against comparable products already making similar claims, so the brand knows exactly where it stands before the claim goes to market or to a regulator.
That third layer is the one brands most often skip, and it’s usually the one that saves the most money later. Finding out during a regulatory review or a competitor challenge that a claim can’t be substantiated for the population it was sold to is a far more expensive problem than scoping the evidence correctly the first time.
Where to go from here
If you’re formulating or making claims for melanin-rich skin and aren’t sure whether your current evidence would hold up to scrutiny, a free 30 minute R&D Diagnostic is the fastest way to find out. In one session, we’ll help you work out whether you need a Discovery Sprint to identify the right active, a Validation Programme to prove an existing one, or both run together as an End-to-End Programme.
Book a free R&D Diagnostic: hexislab.com/rd-diagnostic
Has your brand had a claim challenged, or held back a launch, because the evidence didn’t specifically cover melanin-rich skin? We’d like to hear about it, tell us in the comments or DM us.
Want this applied to your own product?